A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib
- DOI
- 10.1038/s41392-025-02481-8
- Published
- 2025-12-02
- Container
- Signal Transduction and Targeted Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41392-025-02481-8,
title = {A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib},
author = {Yuankai Shi and Dongqing Lv and Weineng Feng and Shuoyan Liu and Puyuan Xing and Yan Yu and Jun Yin and Xiubao Ren and Junqiang Zhang and Gaohua Han and Yongchang Zhang and Shundong Cang and Jun Chen and Enguo Chen and Lingxin Meng and Yong Zhang},
year = {2025},
journal = {Signal Transduction and Targeted Therapy},
doi = {10.1038/s41392-025-02481-8},
url = {https://doi.org/10.1038/s41392-025-02481-8}
}RIS
TY - JOUR TI - A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib AU - Yuankai Shi AU - Dongqing Lv AU - Weineng Feng AU - Shuoyan Liu AU - Puyuan Xing AU - Yan Yu AU - Jun Yin AU - Xiubao Ren AU - Junqiang Zhang AU - Gaohua Han AU - Yongchang Zhang AU - Shundong Cang AU - Jun Chen AU - Enguo Chen AU - Lingxin Meng AU - Yong Zhang PY - 2025 JO - Signal Transduction and Targeted Therapy DO - 10.1038/s41392-025-02481-8 UR - https://doi.org/10.1038/s41392-025-02481-8 ER -
APA
Shi, Y., Lv, D., Feng, W., Liu, S., Xing, P., Yu, Y., Yin, J., Ren, X., Zhang, J., Han, G., Zhang, Y., Cang, S., Chen, J., Chen, E., Meng, L., & Zhang, Y. (2025). A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02481-8
Source records
- crossref · retrieved 2026-09-26T21:02:40.795Z